Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-25 @ 9:27 PM
Study NCT ID:
NCT01300156
Status:
UNKNOWN
Last Update Posted:
2011-02-21
First Post:
2011-02-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
Sponsor:
National Cancer Center, Korea
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
NCCCTS-10-524
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Hyeon-Seok Eom / MD, PhD
Old Organization:
Natioinal Cancer Center, Korea